-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 17, 2021, Pfizer and BioNTech announced that they will modify a large-scale clinical trial to evaluate their new crown vaccine for children 6 months to 5 years old
This large-scale clinical trial enrolled 4,500 children from 6 months to under 12 years old (regardless of previous evidence of new coronavirus infection), and aimed to evaluate the Pfizer/BioNTech vaccine two-dose vaccination regimen (with an interval of about 21 days) at 3 ages Safety, tolerability and immunogenicity in the group (5 years old to under 12 years old; 2 years old to under 5 years old; 6 months to under 2 years old)
Although the trial is still ongoing and remains blind, the researchers performed a pre-specified immunogenicity analysis on a subset of subjects one month after the second vaccination
In addition, Pfizer and BioNTech have initiated a low-dose level sub-test of 10 µg or 30 µg in approximately 600 cases of 12-17 year-old adolescents to evaluate the safety and immunogenicity of the third dose of the new crown vaccine
Reference materials:
[1] Pfizer And Biontech Provide Update On Ongoing Studies Of Covid-19 Vaccine.
[2] Pfizer Plans To Study A Third Shot For Its Covid-19 Vaccine In The Youngest Kids, Pushing Back Its Timeline Farther.
